

## PRODUCT SUPPLY UPDATE

## Dear Healthcare Professional,

This communication is to inform you of the current supply shortage of all strengths (20 mg, 30 mg and 60 mg) of ADALAT® XL® (nifedipine extended-release tablets) in Canada. ADALAT® XL® is manufactured by Bayer Inc., and distributed in Canada by TEVA.

In order to best provide for supply to patients and maximize overall production output, Bayer is focusing supply on the 30 mg dose. As a consequence, the ADALAT® XL® 20 and 60 mg dosage strengths will no longer be available once existing supplies are depleted. The period of supply interruption of these dosage strengths is indeterminate at this time. Please take this supply shortage into consideration when assessing the initiation of new patients on ADALAT® XL®.

Please note that this communication is not intended to provide medical advice or replace your clinical judgement. Bayer does not recommend use of ADALAT® XL® beyond the information found in the Canadian Product Monograph. A copy of the ADALAT® XL® Product Monograph can be found at www.bayer.ca.

If you require additional information regarding this product shortage or have clinical questions about ADALAT® XL®, please contact Bayer Canada Medical Information via website <a href="www.medinfo.bayer.ca">www.medinfo.bayer.ca</a>, by email at <a href="canada.medinfo@bayer.com">canada.medinfo@bayer.com</a> or by phone at 1-800-265-7382.

Sincerely,

Shurjeel Choudhri BSc(med) MD FRCPC

Senior Vice President and Head, Medical & Scientific Affairs

Bayer Inc.